Geode Capital Management LLC Trims Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Geode Capital Management LLC reduced its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 1.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,447,512 shares of the company’s stock after selling 68,026 shares during the quarter. Geode Capital Management LLC owned 2.05% of X4 Pharmaceuticals worth $2,308,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in X4 Pharmaceuticals during the 3rd quarter worth $340,000. K2 Principal Fund L.P. acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $284,000. AQR Capital Management LLC raised its stake in shares of X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares in the last quarter. State Street Corp lifted its holdings in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after buying an additional 189,105 shares during the period. Finally, Barclays PLC boosted its stake in shares of X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after buying an additional 183,861 shares in the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $0.70 on Wednesday. The stock’s 50 day moving average price is $0.54 and its 200 day moving average price is $0.63. The firm has a market cap of $119.72 million, a P/E ratio of -7.80 and a beta of 0.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. X4 Pharmaceuticals, Inc. has a 1 year low of $0.26 and a 1 year high of $1.60.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on XFOR shares. HC Wainwright cut their price target on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Stifel Nicolaus dropped their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.